Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-15 07:00 |
Biophytis files a patent application and strengthens its intellectual property …
|
English | 314.5 KB | ||
| 2024-04-15 07:00 |
Biophytis dépose une demande de brevet et renforce sa propriété intellectuelle …
|
French | 321.9 KB | ||
| 2024-04-08 23:12 |
Biophytis announces its 2023 financial results and provides an update on its b…
|
English | 494.1 KB | ||
| 2024-04-08 23:12 |
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activ…
|
French | 241.0 KB | ||
| 2024-04-08 23:10 |
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydrox…
|
English | 199.5 KB | ||
| 2024-04-08 23:10 |
Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-…
|
French | 206.2 KB | ||
| 2024-04-04 23:00 |
RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
|
English | 167.4 KB | ||
| 2024-04-04 23:00 |
RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024
|
French | 179.3 KB | ||
| 2024-03-22 07:00 |
Biophytis presented its phase 3 protocol in the treatment of sarcopenia
|
English | 189.3 KB | ||
| 2024-03-22 07:00 |
Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopén…
|
French | 175.9 KB | ||
| 2024-03-18 07:00 |
Assemblée générale mixte du 02 avril 2024
|
French | 177.3 KB | ||
| 2024-03-15 23:00 |
Biophytis announces the implementation of a reverse stock split of its ordinar…
|
English | 206.3 KB | ||
| 2024-03-15 23:00 |
Biophytis annonce le lancement du regroupement des actions composant son capita…
|
French | 212.3 KB | ||
| 2024-03-12 07:00 |
Biophytis announces its participation in several events in Europe and the Unite…
|
English | 184.5 KB | ||
| 2024-03-12 07:00 |
Biophytis annonce sa participation à plusieurs événements en Europe et aux Eta…
|
French | 192.3 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
